((自动化翻译由路透提供，请见免责声明 ))
11月14日 - ** 眼药生产商哈罗公司 股价盘前下跌24.7%至39美元
** 该公司第三季度营收（(link)）增长43.8%至4930万美元，低于LSEG统计的预期5280万美元。
** HROW 未计利息、税项、折旧及摊销前的利润为 880 万美元，低于预期的 1170 万美元。
** 季度报告每股亏损 12 美分
** 在收入同比增长 44% 的同时，公司实现了收入的小幅连续增长，尽管第三季度是传统的夏季季节性旺季，而且运营方面的影响将第三季度的部分收入推到了第四季度 - 首席执行官 Mark L. Baum
** 4 家券商的平均评级为 "买入"；PT 中值为 60 美元--LSEG 数据
** 截至上一交易日收盘，该公司股价已上涨了四倍多。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.